Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast.

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

DexCom (NASDAQ: DXCM) is gearing up to announce its quarterly earnings on Thursday, 2026-02-12. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which ...

Good news for anyone who thought Fitbit's move toward the smartwatch market would be a move away from health: The wearable maker has just announced a partnership with Dexcom that will bring data from ...

DexCom is expected to remain an outperformer in the healthcare sector in 2024, driven by M&A activity and the growth of GLP-1 weight loss drugs. The company's continuous glucose monitoring ("CGM") ...

We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other Friday’s top ...

DexCom is a leading healthcare stock that has seen significant growth, with shares returning close to 1,400% in the past decade. DXCM stock has faced resistance and is currently 37% below its all-time ...

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 3.7% in the afternoon session after it rebounded from a steep sell-off that was triggered by its long-term revenue growth outlook. The ...